Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelBoehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as Share XBoehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelhttps://pharmaphorum.com/news/boehringer-lillys-jardiance-ties-to-match-azs-farxiga-with-heart-failure-label/
Moderna’s COVID-19 vaccine is third approved in UKThe UK has approved the Moderna coronavirus vaccine, hard on the heels of its go-ahead in Europe, although Share XModerna’s COVID-19 vaccine is third approved in UKhttps://pharmaphorum.com/news/modernas-covid-19-vaccine-is-third-approved-in-uk/
Unconvinced by NHS test run, NICE rejects BMS’ Opdivo in head and neck cancerNICE has rejected Bristol Myers Squibb’s immunotherapy Opdivo as a second-line treatment for head and neck cancer in Share XUnconvinced by NHS test run, NICE rejects BMS’ Opdivo in head and neck cancerhttps://pharmaphorum.com/news/unconvinced-by-nhs-test-run-nice-rejects-bms-opdivo-in-head-and-neck-cancer/
UK left trailing as EU quickly approves Moderna’s COVID-19 vaccineThe European Union has approved the coronavirus vaccine from Moderna, leaving the UK trailing because of changes to Share XUK left trailing as EU quickly approves Moderna’s COVID-19 vaccinehttps://pharmaphorum.com/news/uk-left-trailing-as-eu-quickly-approves-modernas-covid-19-vaccine/
FDA and doctors warn against extending COVID-19 vaccine dose gapTinkering with the dosing schedule of COVID-19 vaccines runs a “significant risk” to public health, the FDA has Share XFDA and doctors warn against extending COVID-19 vaccine dose gaphttps://pharmaphorum.com/news/fda-and-doctors-warn-against-extending-covid-19-vaccine-dose/
UK rolls out Oxford Uni/AZ COVID-19 shot as cases soarThe first people are receiving the COVID-19 vaccine from Oxford University and AstraZeneca in the UK, as prime Share XUK rolls out Oxford Uni/AZ COVID-19 shot as cases soarhttps://pharmaphorum.com/news/uk-rolls-out-oxford-uni-az-covid-19-shot-as-cases-soar/
AZ COVID-19 vaccine cleared in UK, dosing to start next weekThe UK has approved AstraZeneca and Oxford University’s COVID-19 vaccine AZD1222 in another significant step forward in the Share XAZ COVID-19 vaccine cleared in UK, dosing to start next weekhttps://pharmaphorum.com/news/az-covid-19-vaccine-cleared-in-uk-dosing-to-start-next-week/
NICE backs AZ’s Forxiga for heart failureJust a few weeks after its EU approval for heart failure, AstraZeneca’s Forxiga has been backed by NICE Share XNICE backs AZ’s Forxiga for heart failurehttps://pharmaphorum.com/news/nice-backs-azs-forxiga-for-heart-failure/
FDA rejects Novartis’ cholesterol drug after factory inspection issueNovartis’ cholesterol drug inclisiran has hit a speed bump with the FDA, which has rejected the potential blockbuster Share XFDA rejects Novartis’ cholesterol drug after factory inspection issuehttps://pharmaphorum.com/news/fda-rejects-novartis-cholesterol-drug-after-missed-factory-inspection/
Moderna’s COVID-19 vaccine is second for US after FDA green lightAs expected, the FDA has moved swiftly ahead with emergency approval of Moderna’s COVID-19 vaccine after a positive Share XModerna’s COVID-19 vaccine is second for US after FDA green lighthttps://pharmaphorum.com/news/modernas-covid-19-vaccine-is-second-for-us-after-fda-green-light/
GSK’s Benlysta claims first FDA okay for lupus kidney damageGlaxoSmithKline’s Benlysta has been on the market for almost a decade, but it still has some tricks up Share XGSK’s Benlysta claims first FDA okay for lupus kidney damagehttps://pharmaphorum.com/news/gsks-benlysta-claims-first-fda-okay-for-lupus-kidney-damage/
Entresto set for big sales hike after FDA panel endorsementNovartis’ Entresto is on course to become the first drug to be approved in the US for a Share XEntresto set for big sales hike after FDA panel endorsementhttps://pharmaphorum.com/news/entresto-set-for-big-sales-hike-after-fda-panel-endorsement/
FDA backs Moderna COVID-19 shot ahead of emergency use voteModerna looks odds on to claim emergency use authorisation from the FDA for its COVID-19 vaccine this week, Share XFDA backs Moderna COVID-19 shot ahead of emergency use votehttps://pharmaphorum.com/news/fda-backs-moderna-covid-19-shot-ahead-of-emergency-use-vote/
Pfizer/BioNTech COVID-19 vaccinations start across the USHospitals in the US have started vaccinating their front-line staff against COVID-19, as deaths in the country crossed Share XPfizer/BioNTech COVID-19 vaccinations start across the UShttps://pharmaphorum.com/news/pfizer-biontech-covid-19-vaccinations-start-across-the-us/
Family doctors begin COVID-19 immunisation drive in UKThe roll-out of the biggest vaccination programme in the history of the UK’s NHS is gathering pace, as Share XFamily doctors begin COVID-19 immunisation drive in UKhttps://pharmaphorum.com/news/family-doctors-begin-covid-19-immunisation-drive-in-uk/
Sanofi/GSK trial woes delay a billion COVID-19 shots by nine monthsSanofi and GlaxoSmithKline have said their COVID-19 vaccine has hit a snag in clinical development, prompting analysts to Share XSanofi/GSK trial woes delay a billion COVID-19 shots by nine monthshttps://pharmaphorum.com/news/sanofi-gsk-trial-woes-delay-a-billion-covid-19-shots-by-nine-months/
CLL patients in England to get AZ’s Calquence after okay from NICENHS England is to grant immediate access to AstraZeneca’s cancer drug Calquence (acalabrutinib) for certain patients with chronic Share XCLL patients in England to get AZ’s Calquence after okay from NICEhttps://pharmaphorum.com/news/cll-patients-in-england-to-get-azs-calquence-after-okay-from-nice/
Bluebird trumpets long-term data from beta-thalassaemia gene therapybluebird bio has presented long-term data from its Zynteglo one-time gene therapy for the blood disorder beta-thalassaemia, as Share XBluebird trumpets long-term data from beta-thalassaemia gene therapyhttps://pharmaphorum.com/news/bluebird-trumpets-long-term-data-from-beta-thalassaemia-gene-therapy/
